Clinical Trial Update: 36-Month Post-marketing Surveillance and Analysis of Menactra Vaccine in 2-10 Year Olds

View source ↗

Summary

36-month post-marketing surveillance of Menactra in 2-10 year olds was completed, with results posted. The study assessed safety and effectiveness in real-world…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningitis
• Meningococcal Disease

Drugs mentioned

• Menactra (Meningococcal conjugate vaccine (A, C, W, Y))

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Meningitis, Meningococcal Disease | Status: COMPLETED | Results posted: 2015-02-12